收藏切换
Exploration of the therapeutic mechanism of mepolizumab in patients with type 2 inflammatory bronchial asthma
收藏切换
Xiaoqin SHENa, Yongwei LIb, Debing ZHOUb, *
World Clinical Drug | 2026, 47(5) : 502 - 507
Less
收藏切换
World Clinical Drug | 2026, 47(5): 502-507
• Article •
Exploration of the therapeutic mechanism of mepolizumab in patients with type 2 inflammatory bronchial asthma
Full
Xiaoqin SHENa, Yongwei LIb, Debing ZHOUb, *
Affiliations
  • a.Department of Respiratory and Critical Care Medicine, Anyue County People's Hospital, Ziyang 642350, Sichuan Province, China
  • b.Department of Clinical Pharmacy, Anyue County People's Hospital, Ziyang 642350, Sichuan Province, China
Published: 2026-05-10 doi: 10.13683/j.wph.2026.05.007
Outline
收藏切换
Objective

To evaluate the therapeutic mechanism of mepolizumab in type 2 inflammatory bronchial asthma.

Methods

The clinical data of 102 patients with type 2 bronchial asthma who were treated in our hospital from March 2024 to January 2025 were collected retrospectively. They were grouped according to different treatment regimens. The control group treated with budesonide formoterol and oral glucocorticosteroid(OCS) prednisone, while the observation group received mepolizumab in addition to the control group. The conditions of both groups after 6 months of treatment were collected and compared, including asthma control test(ACT) score, OCS dosage, eosinophil(EOS) count,immunoglobulin(Ig)E, fractional exhaled nitric oxide(FeNO), forced vital capacity(FVC), forced expiratory volume in one second(FEV1), peak expiratory flow(PEF), total bronchial surface area(TA), lumen area(LA), and wall area of tube(WA), and the number of readmissions due to asthma exacerbation over a 12-month follow-up period.

Results

After treatment, the ACT score and OCS dosage in the observation group decreased more significantly compared with the control group(P<0.05), while the EOS count, IgE, and FeNO were lower in the observation group than in the control group(P<0.05), and the FVC, FEV1/FVC, and PEF in the observation group were higher than those in the control group(P<0.05).The LA in the observation group was higher than that in the control group(P<0.05), and the WA was lower than that in the control group(P<0.05), the 12-month follow-up showed that the number of re-admissions due to asthma exacerbation in the observation group was less than those in the control group(P<0.05). The multivariate logistic regression analysis showed that baseline EOS and FeNO were independent predictors for evaluating treatment response based on the ACT scoring(P<0.05).

Conclusion

Mepolizumab helps control the condition of type 2 inflammatory bronchial asthma, reduces the dosage of OCS. The main mechanism of action is speculated to be targeting the blockade of type 2 inflammatory biomarkers and improving airway remodeling.

type 2 inflammatory bronchial asthma  /  mepolizumab  /  glucocorticosteroid  /  pulmonary function  /  airway remodeling
沈小钦, 李永伟, 周德兵. 美泊利珠单抗对2型炎症支气管哮喘患者的治疗机制探索. 世界临床药物, 2026 , 47 (5) : 502 -507 . DOI: 10.13683/j.wph.2026.05.007
Xiaoqin SHEN, Yongwei LI, Debing ZHOU. Exploration of the therapeutic mechanism of mepolizumab in patients with type 2 inflammatory bronchial asthma[J]. World Clinical Drug, 2026 , 47 (5) : 502 -507 . DOI: 10.13683/j.wph.2026.05.007
Year 2026 volume 47 Issue 5
57
13
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.05.007
  • Receive Date:2025-08-25
  • Online Date:2026-11-05
  • Published:2026-05-10
Article Data
Affiliations
History
  • Received:2025-08-25
  • Revised:2026-04-12
Affiliations
    a.Department of Respiratory and Critical Care Medicine, Anyue County People's Hospital, Ziyang 642350, Sichuan Province, China
    b.Department of Clinical Pharmacy, Anyue County People's Hospital, Ziyang 642350, Sichuan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.05.007
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT